Close

China’s Innovent and Eli Lilly partner to develop three new cancer treatments

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Litmys and PharmaACE Establish Strategic Partnership for Market Projections

Life sciences consulting firms Litmys and PharmaACE have officially...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...
- Advertisement -

US-based Eli Lilly and Company has partnered with Chinese drug development firm Innovent Biologics to develop and commercialise three cancer treatments over the next decade.

The deal will expand the presence of both firms in the oncology market of China, according to Innovent.

Innovent Biologics co-founder, president and CEO Dr Michael Yu said: “This groundbreaking collaboration establishes Innovent as the very first company in China to form such a broad alliance with a global pharmaceutical company, and we are honoured to collaborate with a company as esteemed as Lilly.”

As part of the deal, Innovent will take the responsibility for development and manufacturing of the drugs in the Chinese market, while Lilly will commercialise the three medicines being developed.

Under the collaboration, Lilly will provide its cMet monoclonal antibody gene for possible treatment of non-small cell lung cancer. In addition, the company will continue the development of cMet monoclonal antibody programme outside of China.
“Innovent will provide its monoclonal antibody targeting protein CD-20 to investigate haematologic malignancies.”

For the programme, Innovent will provide its monoclonal antibody targeting protein CD-20 to investigate haematologic malignancies. The company obtained investigational new drug approval in China to begin Phase I development of this therapy.

The company will contribute a pre-clinical immuno-oncology molecule to develop in China, while Lilly will take the responsibility for development, manufacturing and commercialisation of this molecule outside the country.

In addition, Lilly will receive rights to develop and commercialise up to three pre-clinical bispecific immuno-oncology molecules outside of China.

Under the agreement, Innovent will secure a total upfront payment of $56m, and Lilly will offer future payments exceeding $400m for the pre-clinical immuno-oncology molecule if the product reaches certain development, regulatory and sales milestones.

The deal also includes sales royalties and other payments on certain products, if commercialised.

 

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Litmys and PharmaACE Establish Strategic Partnership for Market Projections

Life sciences consulting firms Litmys and PharmaACE have officially...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...

How Biopharmaceutical Research Is Shaping the Future of Cancer Treatment

Cancer is no longer viewed solely as a clinical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »